Previous 10 | Next 10 |
2023-08-10 10:46:32 ET Cabaletta Bio press release ( NASDAQ: CABA ): Q2 GAAP EPS of -$0.37. As of June 30, 2023, Cabaletta had cash, cash equivalents and short-term investments of $176.3 million, compared to $106.5 million as of December 31, 2022. For further details...
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $100M public offering extending cash runway into the fourth quarter of 2025 – PHILADELPHIA, Aug....
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology c...
2023-07-19 18:15:34 ET Guggenheim has initiated coverage of Cabaletta Bio ( NASDAQ: CABA ) with a buy rating, citing the potential of its CD19 CAR-T cell therapy CABA-201. The investment bank said in a note that it sees global peak sales of around $1.9B for the product if it's a...
2023-07-19 17:30:09 ET Gainers: Zions Bancorporation ( ZION ) +8% . Heritage-Crystal Clean ( HCCI ) +7% . CareMax ( CMAX ) +5% . Cabaletta ( CABA ) +5% . AlloVir ( ALVR ) +4% . Losers: Richardson Electronics ( REL...
2023-07-18 14:58:08 ET Shares of Cabaletta Bio (NASDAQ: CABA) were up more than 12% as of 2:40 p.m. ET Tuesday, after rising as much as 12.7% earlier in the day. The clinical-stage biotech company received an analyst upgrade. Cabaletta didn't have any major announcements or ...
Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved 7.45% on the day to $13.42. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B ...
Cabaletta Bio, Inc. (NASDAQ: CABA) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.51% on the day to $12.04. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B...
2023-07-12 02:15:37 ET Summary Cabaletta Bio is a clinical-stage biotech company developing engineered T-cell therapies for autoimmune diseases, with its CABA-201 therapy recently approved for Phase 1/2 clinical trials by the FDA. Despite a decrease in cash reserves, the company's...
2023-06-21 10:17:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spotify (NYSE: SPOT ) stock is moving on Wednesday following an upgrade from Wolfe Research analyst Zach Morrissey. The Wolfe Research analyst upgraded shares of SPOT from a...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...